Clinical Trial Update: HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating HMPL-453 (FGFR inhibitor) combined with chemotherapy or anti-PD-1 antibody in advanced solid tumors; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• HMPL-453

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: UNKNOWN